Factors Associated With Epinephrine Use in the Treatment of Anaphylaxis in Infants and Toddlers.

Allergic reaction Anaphylaxis Anaphylaxis action plan Epinephrine Food allergy Infant Toddler

Journal

The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220

Informations de publication

Date de publication:
02 Nov 2023
Historique:
received: 31 05 2023
revised: 13 10 2023
accepted: 27 10 2023
pubmed: 6 11 2023
medline: 6 11 2023
entrez: 3 11 2023
Statut: aheadofprint

Résumé

Undertreatment of anaphylaxis with epinephrine continues to be an unmet need and is a particular challenge among infants and toddlers. To address this gap by identifying barriers and solutions to appropriate and timely administration of epinephrine. We conducted a national online survey among primary caregivers of children who experienced a severe food-induced allergic reaction when younger than 36 months. Outcomes of interest included epinephrine use in community and health care settings to treat probable anaphylaxis. Of 264 probable anaphylaxis cases, 39% of infants (aged <12 months) and 61% of toddlers (aged 12-35 months) received epinephrine at any time during the child's most severe allergic reaction (P = .001). A previous diagnosis of a food allergy was reported in 62% of cases where epinephrine was used compared with 26% of cases where epinephrine was not used (P < .001). In children with a previous diagnosis of a food allergy, epinephrine was used in 89% of those who were prescribed an anaphylaxis action plan compared with 50% of those without a plan (P = .001). The adjusted odds ratio for the association between having an anaphylaxis action plan and epinephrine use in cases of probable anaphylaxis was 5.39 (95% confidence interval, 2.18-13.30). Epinephrine use at any time (including in health care settings) during probable anaphylaxis is more likely in infants and toddlers with a previously diagnosed food allergy than those without diagnosis. The provision of an anaphylaxis action plan is also associated with increased epinephrine use during probable anaphylaxis in this population.

Sections du résumé

BACKGROUND BACKGROUND
Undertreatment of anaphylaxis with epinephrine continues to be an unmet need and is a particular challenge among infants and toddlers.
OBJECTIVE OBJECTIVE
To address this gap by identifying barriers and solutions to appropriate and timely administration of epinephrine.
METHODS METHODS
We conducted a national online survey among primary caregivers of children who experienced a severe food-induced allergic reaction when younger than 36 months. Outcomes of interest included epinephrine use in community and health care settings to treat probable anaphylaxis.
RESULTS RESULTS
Of 264 probable anaphylaxis cases, 39% of infants (aged <12 months) and 61% of toddlers (aged 12-35 months) received epinephrine at any time during the child's most severe allergic reaction (P = .001). A previous diagnosis of a food allergy was reported in 62% of cases where epinephrine was used compared with 26% of cases where epinephrine was not used (P < .001). In children with a previous diagnosis of a food allergy, epinephrine was used in 89% of those who were prescribed an anaphylaxis action plan compared with 50% of those without a plan (P = .001). The adjusted odds ratio for the association between having an anaphylaxis action plan and epinephrine use in cases of probable anaphylaxis was 5.39 (95% confidence interval, 2.18-13.30).
CONCLUSIONS CONCLUSIONS
Epinephrine use at any time (including in health care settings) during probable anaphylaxis is more likely in infants and toddlers with a previously diagnosed food allergy than those without diagnosis. The provision of an anaphylaxis action plan is also associated with increased epinephrine use during probable anaphylaxis in this population.

Identifiants

pubmed: 37923127
pii: S2213-2198(23)01204-7
doi: 10.1016/j.jaip.2023.10.049
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Michael Pistiner (M)

Mass General for Children, Harvard Medical School, Boston, Mass. Electronic address: mpistiner@mgh.harvard.edu.

Jose Euberto Mendez-Reyes (JE)

Mass General for Children, Harvard Medical School, Boston, Mass.

Sanaz Eftekhari (S)

Asthma and Allergy Foundation of America, Arlington, Va.

Melanie Carver (M)

Asthma and Allergy Foundation of America, Arlington, Va.

Jay Lieberman (J)

The University of Tennessee Health Science Center, LeBonheur Children's Hospital, Memphis, Tenn.

Julie Wang (J)

Department of Pediatrics, Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.

Carlos A Camargo (CA)

Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

Classifications MeSH